Samuel Bates Martin - 10 Aug 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Issuer symbol
CLDX
Transactions as of
10 Aug 2021
Net transactions value
-$207
Form type
4
Filing time
12 Aug 2021, 10:00:22 UTC
Previous filing
21 Jun 2021
Next filing
17 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $92,888 +10,302 +96% $9.02 21,037 10 Aug 2021 Direct F1, F2
transaction CLDX Common Stock Sale $93,034 -2,056 -9.8% $45.25 18,981 10 Aug 2021 Direct F1, F3
transaction CLDX Common Stock Options Exercise $30,800 +11,079 +58% $2.78* 30,060 10 Aug 2021 Direct
transaction CLDX Common Stock Sale $30,860 -682 -2.3% $45.25 29,378 10 Aug 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -10,302 -39% $0.000000 16,030 10 Aug 2021 Common Stock 10,302 $9.02 Direct F2, F4
transaction CLDX Incentive Stock Option Options Exercise $0 -11,079 -26% $0.000000 31,921 10 Aug 2021 Common Stock 11,079 $2.78 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F3 Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.
F4 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.